Amneal Pharmaceuticals Management
Management criteria checks 4/4
Amneal Pharmaceuticals' CEO is Chirag Patel, appointed in Jan 2005, has a tenure of 19.92 years. total yearly compensation is $2.37M, comprised of 31.6% salary and 68.4% bonuses, including company stock and options. directly owns 7.03% of the company’s shares, worth $175.78M. The average tenure of the management team and the board of directors is 5.4 years and 6.6 years respectively.
Key information
Chirag Patel
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 31.6% |
| CEO tenure | 19.9yrs |
| CEO ownership | 7.0% |
| Management average tenure | 5.4yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$184m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
| Sep 30 2019 | n/a | n/a | -US$339m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$325k | n/a | -US$21m |
Compensation vs Market: Chirag's total compensation ($USD2.37M) is below average for companies of similar size in the US market ($USD6.56M).
Compensation vs Earnings: Chirag's compensation has been consistent with company performance over the past year.
CEO
Chirag Patel (57 yo)
19.9yrs
Tenure
US$2,370,385
Compensation
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.9yrs | US$2.37m | 7.03% $ 175.8m | |
| Co-Founder | 22.9yrs | US$2.37m | 8.15% $ 203.9m | |
| Executive VP & CFO | 4.8yrs | US$1.89m | 0.17% $ 4.3m | |
| Senior VP | 2.9yrs | US$1.35m | 0% $ 0 | |
| Executive VP & Chief Human Resources Officer | 10.9yrs | US$1.53m | 0.094% $ 2.4m | |
| Executive VP & Chief Commercial Officer of Generics | 6.8yrs | US$1.94m | 0.083% $ 2.1m | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | 1.9yrs | no data | no data | |
| Senior VP of Strategic Sourcing & Supply Management | 1.9yrs | no data | no data | |
| Chief Quality Officer | 5.9yrs | no data | no data | |
| Senior VP & Chief Scientific Officer of Generics | 4.9yrs | no data | no data | |
| Vice President & Head of Medical Affairs | no data | no data | no data |
5.4yrs
Average Tenure
54.5yo
Average Age
Experienced Management: AMRX's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.9yrs | US$2.37m | 7.03% $ 175.8m | |
| Co-Founder | 22.9yrs | US$2.37m | 8.15% $ 203.9m | |
| Independent Chairman of the Board | 5.3yrs | US$299.08k | 0.23% $ 5.9m | |
| Independent Director | 6.6yrs | US$302.20k | 0.085% $ 2.1m | |
| Independent Director | 6.6yrs | US$244.70k | 0.097% $ 2.4m | |
| Independent Director | 5yrs | US$254.70k | 0.079% $ 2.0m | |
| Independent Director | 5yrs | US$277.20k | 0.087% $ 2.2m | |
| Director | 6.6yrs | US$217.20k | 0.66% $ 16.5m | |
| Independent Director | 2.4yrs | US$267.04k | 0.017% $ 431.1k | |
| Independent Director | 6.6yrs | US$217.20k | 0.081% $ 2.0m | |
| Independent Director | 5yrs | US$284.70k | 0.086% $ 2.2m |
6.6yrs
Average Tenure
57yo
Average Age
Experienced Board: AMRX's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 02:08 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |